Stabilize Business Operations by Systematically Eliminating Waste & Building a Culture of Continuous Improvement to Deliver Advanced Therapies Just-in-Time for All Patients

Full Event Guide

Welcome to the LEAN Cell & Gene D.C. Summit!

Manufacturing Advanced Therapies Just-In-Time for All Patients

The cell and gene therapy field has seen real breakthroughs, life-changing treatments, growing clinical validation, and a number of approved products. Yet, challenges remain: capital is limited, resources are tight, and many organizations are facing pressure to do more with less.

That’s where the LEAN Cell & Gene Event Series comes in. Designed for those working across development and manufacturing, this series offers a fresh perspective on how LEAN thinking can support better decisions, stronger operations, and more resilient organizations.

Event Guide

What is LEAN?

LEAN is a proven framework from manufacturing industries that focuses on eliminating waste, streamlining processes, and driving continuous improvement. In cell and gene therapy, it means:

1.

Reducing inefficiencies in development, manufacturing, quality, and supply chains

2.

Improving consistency and reliability of processes without adding unnecessary cost

3.

Empowering teams to make smarter, data-driven decisions faster

4.

Building resilience so organizations can scale therapies sustainably

 

Applied effectively, LEAN helps developers deliver therapies to patients more quickly, at lower cost, and with greater quality ensuring advanced therapies don’t stay niche but become accessible at scale.

World-Class Speaker Faculty Includes:

Beau Webber

Associate Professor

University of Minnesota

Eric Tran

Associate Member

Earle A. Chiles Research Institute - Providence Cancer Institute

Gerhard Bauer

Founder & President

GBauerGMP

Katie McKenna

Assistant Professor

Center for Cell & Gene Therapy Baylor College of Medicine

Ramya Tunuguntla

Director Process Development

Stanford Medicine Center for Cancer Cell Therapy

Zulmarie Franco

Biologist

National Cancer Institute

Register

Attend the LEAN Cell & Gene Summit to:

Hear from LEAN Cell & Gene Leaders

Learn how LEAN principles are being successfully applied in CGT to reduce manufacturing overhead, shorten development timelines, and improve cost-efficiency across the product lifecycle

Stabilize Operations

Hear from leading academic, clinical, and commercial CGT institutions on practical ways to stabilize operations and do more with less

Logarithmically Increase Throughput

Explore how a G-Rex production system enables higher throughput through parallel processing, shorter cycle times, and single-piece (continuous) flow

Structurally Reduce Cost

Review how operational excellency and continuous improvement can lead to structurally reduced cost through the systematic identification and elimination of waste

Achieve Total Patient Access

Connect with peers and industry leaders during sessions and networking opportunities to exchange ideas on how we can deliver quality drug product just-in-time to the total addressable patient population

“CGT companies are now faced with a mission critical challenge of preserving capital and establishing a truly scalable manufacturing platform.

Virtually every other industry has met that challenge by adopting LEAN manufacturing principles.

The time has arrived for the CGT field get on board.”

John Wilson, Co-Inventor of G-Rex & Chief Executive Officer, Wilson Wolf

“The many patients in need of a curative CAR T cell therapy should have the option to receive it,  promptly,  reliably,  and at an affordable price.

This is not possible without  LEAN manufacturing.”

Gerharhd Bauer, President, GBauer GMP

ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.

The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs.

CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.

Learn More